Close
Close
Research News

Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society’s 2018 Annual Meeting

2.71428571429
2.7 from 7 votes
Monday, March 12, 2018

Dublin, Ireland – Shire plc, the global biotechnology leader in rare diseases, today announced that it will share new data on recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) and on the management of chronic hypoparathyroidism at the upcoming Endocrine Society's 100th Annual Meeting and Exposition (ENDO), on March 17–20 in Chicago, Illinois.

Hypoparathyroidism is a rare endocrine disease that occurs when inadequate levels of parathyroid hormone (PTH) are secreted by the parathyroid glands, resulting in a mineral imbalance in the body expressed by a low concentration of calcium (hypocalcemia) and a high concentration of phosphate (hyperphosphatemia) in the blood.1 It is estimated that the total number of people with hypoparathyroidism in the United States is about 77,000.2 Hypoparathyroidism can have a significant impact on patients through physical and cognitive symptoms.3,4

"Patients with hypoparathyroidism can experience multiple symptoms and a reduced health-related quality of life," said Howard Mayer M.D., Senior Vice President and Chief Medical Officer, Shire. "With our continuing program of clinical and real-world insights on the chronic form of this rare endocrine disease, we are committed to expand the understanding of the long-term burden of the disease for patients. At ENDO we will be sharing new data in chronic hypoparathyroidism to help healthcare professionals improve the management of their patients."

The latest data will reveal clinical and real-world insights into chronic hypoparathyroidism, including effects on renal parameters,5 impact on health-related quality-of-life scores,6 and an analysis of the latest five-year results from the ongoing RACE study.7 These data demonstrate Shire's long-term commitment to advancing understanding of this rare condition in order to further meet the needs of people living with chronic hypoparathyroidism.

Shire will have two poster presentations and one oral presentation on chronic hypoparathyroidism and will be hosting an exhibit at Booth #4220.

Comparison of three-year estimated glomerular filtration rates between rhPTH(1-84)-treated patients with chronic hypoparathyroidism and a historical control cohort 5 Poster #MON-453 / MON-453

Symptom burden and HRQoL reported among patients with chronic hypoparathyroidism: impact of treatment with rhPTH (1-84) and with standard therapy 6 Poster #MON-452 / MON-452

Five-year efficacy and safety of rhPTH(1-84) for the treatment of adults with chronic hypoparathyroidism: analysis from the open-label RACE study 7 Oral presentation #OR20-3

All abstracts are available on the ENDO website at http://www.abstractsonline.com/pp8/#!/4482.

About NATPARA® (parathyroid hormone) for Injection
NATPARA, available as 25, 50, 75, and 100 mcg per dose strength, is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations. NATPARA was not studied in patients with acute post-surgical

Contact
Investor Relations
Christoph Brackmann
christoph.brackmann@shire.com
+41 795 432 359

Sun Kim
sun.kim@shire.com
+1 617 588 8175

Robert Coates
rcoates@shire.com
+44 203 549 0874

Media
Annabel Cowper
annabel.cowper@shire.com
+41 79 630 8619

Gwen Fisher
gfisher@shire.com
+1 215 482 9649

Source: Shire plc
2.71428571429
2.7 from 7 votes
Free Newsletter
Videos